


FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				INE 109	
				U.S. APPLICATION NO. (If known, see 37 CFR 1.5 60/18,657/980641	
INTERNATIONAL APPLICATION NO. PCT/GB00/01861		INTERNATIONAL FILING DATE 15 May 2000 (15.05.00)		PRIORITY DATE CLAIMED 18 May 1999 (18.05.99)	
TITLE OF INVENTION PRODUCTION OF 1,1,1,2,3,3,3-HEPTAFLUOROPROPANE					
APPLICANT(S) FOR DO/EO/US Robin Riyadh GIBSON and Greg Lyndon SUMMERS					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under <del>PCT Article 34</del> PCT Article 34.</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</p> <p>14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: - Also enclosed: Form PCT/IB/306, PCT/IB/308 and PCT/IPEA/416</p>					
"Express Mail" Mailing Label No.: EL 845496621 US					

U.S. APPLICATION NO. (if known) <b>09/980641</b>		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER																																																														
<div>21. <input type="checkbox"/> The following fees are submitted:</div> <div><b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b></div> <div>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. . . . . <b>\$1040.00</b></div> <div>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . . . <b>\$890.00</b></div> <div>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . . <b>\$740.00</b></div> <div>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . . <b>\$710.00</b></div> <div>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) . . . . . <b>\$100.00</b></div> <div><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div> <div>Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</div> <table border="1" style="width:100%; border-collapse: collapse;"><thead><tr><th style="width:15%;">CLAIMS</th><th style="width:20%;">NUMBER FILED</th><th style="width:20%;">NUMBER EXTRA</th><th style="width:20%;">RATE</th><th style="width:25%;">\$</th></tr></thead><tbody><tr><td>Total claims</td><td>8 - 20 =</td><td>0</td><td>x <b>\$18.00</b></td><td>\$</td></tr><tr><td>Independent claims</td><td>1 - 3 =</td><td>0</td><td>x <b>\$84.00</b></td><td>\$</td></tr><tr><td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td><td>+ <b>\$280.00</b></td></tr><tr><td colspan="4"><b>TOTAL OF ABOVE CALCULATIONS =</b></td><td><b>\$ 890.00</b></td></tr><tr><td colspan="4"><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.</td><td>\$</td></tr><tr><td colspan="4"><b>SUBTOTAL =</b></td><td><b>\$ 890.00</b></td></tr><tr><td colspan="4">Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td><td>\$</td></tr><tr><td colspan="4"><b>TOTAL NATIONAL FEE =</b></td><td>\$</td></tr><tr><td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +</td><td>\$</td></tr><tr><td colspan="4"><b>TOTAL FEES ENCLOSED =</b></td><td><b>\$ 890.00</b></td></tr><tr><td colspan="4" rowspan="2"></td><td><b>Amount to be refunded:</b></td><td>\$</td></tr><tr><td><b>charged:</b></td><td>\$</td></tr></tbody></table> <div>a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>890.00</u> to cover the above fees is enclosed.</div> <div>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</div> <div>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50/1039</u>. A duplicate copy of this sheet is enclosed.</div> <div>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.</div> <div><div><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b></div><div>SEND ALL CORRESPONDENCE TO: Andrew G. Kolomayets Cook, Alex, McFarron, Manzo, Cummings &amp; Mehler, Ltd. 200 West Adams Street - Suite 2850 Chicago, IL 60606 USA (312) 236-8500</div><div><div> SIGNATURE</div><div>Andrew G. Kolomayets NAME</div><div>33,723 REGISTRATION NUMBER</div></div></div>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	8 - 20 =	0	x <b>\$18.00</b>	\$	Independent claims	1 - 3 =	0	x <b>\$84.00</b>	\$	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ <b>\$280.00</b>	<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 890.00</b>	<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	<b>SUBTOTAL =</b>				<b>\$ 890.00</b>	Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	<b>TOTAL NATIONAL FEE =</b>				\$	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$	<b>TOTAL FEES ENCLOSED =</b>				<b>\$ 890.00</b>					<b>Amount to be refunded:</b>	\$	<b>charged:</b>	\$
				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																																																										
Total claims	8 - 20 =	0	x <b>\$18.00</b>	\$																																																														
Independent claims	1 - 3 =	0	x <b>\$84.00</b>	\$																																																														
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ <b>\$280.00</b>																																																														
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 890.00</b>																																																														
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$																																																														
<b>SUBTOTAL =</b>				<b>\$ 890.00</b>																																																														
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$																																																														
<b>TOTAL NATIONAL FEE =</b>				\$																																																														
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$																																																														
<b>TOTAL FEES ENCLOSED =</b>				<b>\$ 890.00</b>																																																														
				<b>Amount to be refunded:</b>	\$																																																													
				<b>charged:</b>	\$																																																													

# DUPLICATE

JC10 Rec'd PCT/PTO 11 5 NOV 2001

U.S. APPLICATION NO. (if known) (37 CFR 1.51) <b>097280641</b>		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
---	--	-------------------------------	--	--------------------------	--

21. <input type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1040.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$890.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$740.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$710.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>          	
				\$ 890.00	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	8 - 20 =	0	x <b>\$18.00</b>	\$	
Independent claims	1 - 3 =	0	x <b>\$84.00</b>	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ <b>\$280.00</b>	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 890.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
<b>SUBTOTAL =</b>				\$ 890.00	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$ 890.00	
				<b>Amount to be refunded:</b>	\$
				<b>charged:</b>	\$

a. ☒ A check in the amount of \$ 890.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 50/1039. A duplicate copy of this sheet is enclosed.


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card  
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Andrew G. Kolomayets  
Cook, Alex, McFarron, Manzo, Cummings & Mehler, Ltd.  
200 West Adams Street - Suite 2850  
Chicago, IL 60606  
USA  
(312) 236-8500

  
SIGNATURE  
Andrew G. Kolomayets  
NAME  
33,723  
REGISTRATION NUMBER

09/980641

JC10 Rec'd PCT/PTO 1 5 NOV 2001

PATENT  
Attorney Docket No. INE 109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: )  
Robin Riyadh GIBSON and )  
Greg Lyndon SUMMERS )  
International Application No.: )  
PCT/GB00/01861 )  
International Application Filing Date: )  
May 15, 2000 )  
Priority Date: May 18, 1999 )  
For: PRODUCTION OF 1,1,1,2,3,3,3- )  
HEPTAFLUOROPROPANE )

<p>CERTIFICATE OF MAILING BY "EXPRESS MAIL"</p> <p>"Express Mail" Mailing Label: <u>EL845496621US</u></p> <p>Date of Deposit <u>November 15, 2001</u></p> <p>I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office Box Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, D.C. 20231</p> <p>NAME <u>Yue X Ruan</u> (TYPED OR PRINTED)</p> <p>SIGNATURE <u>Yue X Ruan</u></p>
--

Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir/Madam:

Please enter this Preliminary Amendment prior to calculating the filing fee.

IN THE CLAIMS:

Please amend Claims 1, 5 and 8 as follows:

1 (Amended). A process for the production of 1,1,1,2,3,3,3-heptafluoropropane (HFC 227ea) by the reaction of hexafluoropropene (HFP) with hydrogen fluoride characterised by the Steps of

A. charging the reaction mixture from the reaction of HFP with hydrogen fluoride to a liquid-phase separator and

allowing an organic phase and a hydrogen fluoride-rich phase to separate under gravity;

- B. recycling the hydrogen fluoride-rich phase separated in Step A to the reactor in which the reaction is carried out;
- C. charging the organic-rich phase separated in Step A to a distillation column;
- D. recovering the HFC 227ea and an hydrogen fluoride-rich mixture separately from the distillation column in Step (C); and
- E. recycling the hydrogen fluoride-rich mixture recovered from Step D to the reactor.

5 (Amended). A process according to Claim 1 in which HFP in addition to that present in the reaction mixture from the reaction of HFP with hydrogen fluoride is introduced into the process.

8 (Amended). A process as claimed in Claim 1 wherein the mixture to be separated in the liquid-phase separator in Step (A) comprises a mole ratio of HF:HFC 227ea of between 3:7 and 6:4.

## REMARKS

This is a Preliminary Amendment to the above-identified patent application. In Claim 1, the second occurrence of "hexafluoropropane" has been deleted and replaced with --

hexafluoropropene-. In line 1 of Claim 5, "any one of the preceding claims" has been deleted and has been replaced with --Claim 1--. In line 1 of Claim 8, "any one of the preceding claims" has been deleted and has been replaced with --Claim 1--.

These amendments are made to remove multiple dependencies in Claims 5 and 8. Favorable consideration and allowance are respectfully requested.

Respectfully submitted,

Andrew G. Kolomayets  
Registration No.: 33,723

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1 (Amended). A process for the production of 1,1,1,2,3,3,3-heptafluoropropane (HFC 227ea) by the reaction of ~~hexafluoropropane~~ hexafluoropropene (HFP) with hydrogen fluoride characterised by the Steps of

- A. charging the reaction mixture from the reaction of HFP with hydrogen fluoride to a liquid-phase separator and allowing an organic phase and a hydrogen fluoride-rich phase to separate under gravity;
- B. recycling the hydrogen fluoride-rich phase separated in Step A to the reactor in which the reaction is carried out;
- C. charging the organic-rich phase separated in Step A to a distillation column;
- D. recovering the HFC 227ea and an hydrogen fluoride-rich mixture separately from the distillation column in Step (C); and
- E. recycling the hydrogen fluoride-rich mixture recovered from Step D to the reactor.

5 (Amended). A process according to ~~any one of the preceding claims~~ Claim 1 in which HFP in addition to that present in the reaction mixture from the reaction of HFP with hydrogen fluoride is introduced into the process.

8 (Amended). A process as claimed in ~~any one of the preceding claims~~ Claim 1 wherein the mixture to be separated in the liquid-phase separator in Step (A) comprises a mole ratio of HF:HFC 227ea of between 3:7 and 6:4.



097980

# Production of 1,1,1,2,3,3,3-heptafluoropropane

The present invention relates to a process for the production of 1,1,1,2,3,3,3-heptafluoropropane from hexafluoropropene and to a process for the separation of mixtures comprising 1,1,1,2,3,3,3-heptafluoropropane and hydrogen fluoride.

Hydrofluorocarbons are widely used as replacements for chlorofluorocarbon compounds in a variety of applications. Such applications include use in medical applications, for example as an aerosol propellant, use as a fire suppressant, use in refrigeration applications and in other applications. 1,1,1,2,3,3,3-heptafluoropropane, which is known in the art as Hydrofluorocarbon 227ea and will hereinafter be referred to as "HFC 227ea" for convenience, has zero ozone depletion potential and is particularly beneficial in medical applications in the light of its combination of properties including low toxicity, non-flammability, solvent properties and boiling point.

It is known to produce hydrofluorocarbons by the hydrofluorination of a fluoroalkene to the corresponding hydrofluoroalkane, optionally in the presence of a catalyst, in the liquid phase or vapour phase. Hydrogen fluoride is known for use as a hydrofluorination agent in such hydrofluorination processes.

A variety of materials may be employed as catalysts in such hydrofluorination processes.

For example, in the vapour phase reaction of hexafluoropropene, hereinafter referred to as "HFP" for convenience, with hydrogen fluoride for the preparation of HFC 227ea, DE 2712732 and GB 902590 disclose the use of a chromium oxyfluoride catalyst and an activated carbon catalyst respectively.

For example, in the liquid phase reaction of HFP with hydrogen fluoride for the preparation of HFC 227ea, WO 97/11042 and WO 96/0243 disclose the use of catalysts comprising an organic amine complexed with hydrogen fluoride and certain antimony catalysts respectively.

The disclosures in the aforementioned patent specifications are incorporated herein by way of reference.

A stoichiometric excess of hydrogen fluoride to HFP is normally employed in the aforementioned processes and the degree of conversion of HFP to HFC 227ea is dependent on *inter alia* the catalyst employed, if any, and the conditions in the reactor in which the conversion is carried out.

The product stream leaving the reactor typically comprises HFC 227ea, HFP, hydrogen fluoride and a ternary azeotrope thereof.

It is normal practice to recover as much as possible of the hydrogen fluoride from the product stream from such hydrofluorination reactions for re-use. This may be partially achieved by distillation. However, the presence in the product stream of an azeotrope or azeotrope-like mixture of HFC 227ea/hydrogen fluoride and an azeotrope or azeotrope-like mixture of HFP/hydrogen fluoride limits the extent to which hydrogen fluoride can be separated from the fluoro-organic compounds by simple distillation.

It is known that the stream comprising the HFC 227ea/hydrogen fluoride azeotrope and the HFP/hydrogen fluoride azeotrope, after recovery of a portion of the hydrogen fluoride by distillation, can be water-washed to allow recovery of both a mixture of organic compounds essentially free of hydrogen fluoride and aqueous hydrogen fluoride. However, such a treatment is wasteful of hydrogen fluoride since it is normal practice for aqueous hydrogen fluoride generated in this way to be neutralised with caustic solution and/or lime and ultimately disposed of.

Alternatively, the product stream from the reaction of a fluoroalkene with hydrogen fluoride, after recovery of a portion of the hydrogen fluoride by distillation, may be treated with a solution of alkali metal dissolved in anhydrous hydrogen fluoride as described in our patent specification WO 97/13179. However, although such a process recovers hydrogen fluoride for re-use within the process, it has the disadvantage of requiring additional equipment.

Furthermore, it is known that in the preparation of fluorine-containing organic compounds by the reaction of a haloalkene with hydrogen fluoride the haloalkene/hydrogen fluoride azeotrope can be separated from the fluorine-containing compound/hydrogen fluoride azeotrope by fractional distillation and hydrogen fluoride can be removed from the fluorine-containing organic compound/hydrogen fluoride azeotrope by treatment with water. However, treatment of the fluorine-containing organic compound/hydrogen fluoride azeotrope with water to remove hydrogen fluoride therefrom involves the use of expensive equipment and is wasteful of hydrogen fluoride.

It will be appreciated that whereas aqueous scrubbing is an effective way of removing hydrogen fluoride from the organic compound(s) after reacting hydrogen fluoride with a haloalkene aqueous scrubbing tends to be expensive in terms of hydrogen fluoride loss from the process. Preferably as much as possible, more preferably





The portion of hydrogen fluoride recovered by distillation in a recovery step prior to Step A, where such a recovery step is carried out, is preferably recycled to the reactor vessel.

In a second embodiment of the process according to the first aspect of the present invention, the product of the reaction of HFP with hydrogen fluoride is charged directly to the liquid-phase separator in Step A.

Where HFC 227ea is prepared by reacting HFP with hydrogen fluoride in the process according to the first aspect of the present invention in the liquid phase in the presence of a catalyst, eg TaF<sub>5</sub>, NbF<sub>5</sub> or SbF<sub>5</sub>, it is suitably carried out at a temperature in the range 20 to 200°C, preferably 40 to 120°C and especially 50 to 100°C. Suitably the reaction is carried out at superatmospheric pressure such that the reactants are in the liquid phase for sufficient time to react to produce HFC 227ea. Preferably the pressure is at least 5 bar and more preferably the pressure is 10 to 50 bar.

The residence time in the reactor in the process according to the first aspect of the present invention is sufficient to permit conversion of HFP feedstock into HFC 227ea. The required residence time will be dependent on *inter alia* the degree of conversion required, the reactant ratio and the reaction conditions.

Where a low conversion rate of HFP into HFC 227ea is desired it is preferable that the feedstocks be recycled to increase the yield of HFC 227ea from the starting material. However, we do not exclude the possibility that recycling is employed where high single pass conversions are required.

In the process according to the present invention the molar ratio of hydrogen fluoride (HF) to HFP fed to the reactor is suitably at least 1:1 and preferably between 1.2 and 10:1. It will be appreciated that where a molar ratio of HF to HFP of 0.1 up to 1:1 is employed the conversion ratio and/or the yield will be lower.

In the process according to the present invention the molar ratio of HFP to the catalyst is suitably not more than 100:1 and is preferably between 1:1 and 50:1.

The levels of HF, HFP and catalyst in the process according to the present invention are suitably selected such that the catalyst and reactants are at least largely dissolved in the liquid phase under the reaction conditions employed.

The process according to the present invention may be operated in batch or continuous mode as desired. Semi-batch operation may also be employed in which one

or more feedstocks are fed continuously to the process and one or more other feedstocks are fed to the process in batch-wise fashion.

Alternatively, the process according to the present invention may be carried out in the vapour phase. Suitable conditions and catalysts for use in carrying out the process according to the present invention in the vapour phase are more fully described in DE 2712732 and GB 902590 mentioned hereinbefore.

The present invention will be further illustrated by reference to the accompanying drawings which illustrate, by way of example only, schematic representations of plants for carrying out the process according to the present invention.

In the drawings:

Figure 1 is a schematic representation of a plant wherein HFP is fed to the liquid-phase separator;

Figure 2 is a schematic representation of a plant wherein HFP is fed to the reactor;

Figure 3 is a schematic representation of a plant wherein the product of the reaction is fed directly to the liquid-phase separator; and

Figure 4 is a ternary diagram illustrating HFC 227ea, HFP and HF separation.

In Figures 1 and 2, feed pipe (1) leads to a reactor (2), which optionally contains a fluorination catalyst. Product pipe (3) from the reactor (2) is in fluid-flow communication with a first distillation column (4), which is for example a single stage flash vessel. Distillation column (4) is typically operated at a pressure of 12 bars with a bottoms temperature of 100°C and a tops temperature of around 50°C. Bottoms pipe (5) from distillation column (4) is in fluid-flow communication with feed-pipe (1). Tops line (6) from distillation column (4) is in fluid-flow communication with a liquid-phase separator (7). Tops line (8) from the liquid-phase separator (7) is in fluid-flow communication with feed-pipe (1). Bottoms line (9) from the liquid-phase separator (7) is in fluid-flow communication with a second distillation column (10), which is for example a packed column. Distillation column (10) is typically operated at a pressure of around 12 bars with a tops temperature of 37°C and a bottoms temperature of around 60°C. Distillation column (10) is provided with an exit pipe for product (11) and a tops pipe (12).

In Figure 1, tops pipe (12) from distillation column (10) is in fluid flow communication with tops line (6) which is provided with a feed-pipe (13).

In Figure 2, tops pipe (12) from distillation column (10) is in fluid flow communication with feed-pipe (1) which is provided with feed-pipe (13).

In operation, in Figures 1 and 2, the reactor (2) is charged through feed pipe (1) with a feed stream containing fresh hydrogen fluoride and recycled hydrogen fluoride (from lines (5) and (8) and, in Figure 2, line (12)). The product from reactor (2) comprising HFC 227ea, hydrogen fluoride and unconverted HFP, often in the form of a ternary azeotrope, travels through product pipe (3) to the first distillation column (4). In distillation column (4), hydrogen fluoride, which is recycled via bottoms line (5) to feed pipe (1), is separated from the mixture of HFC 227ea, hydrogen fluoride and unconverted HFP. The mixture of HFC 227ea, residual hydrogen fluoride and HFP is fed via tops line (6) from the distillation column (4) to the liquid-phase separator (7). The liquid-phase separator (7) is typically operated at 0-20°C to afford better separation. In Figure 1, HFP is fed via feed line (13) to liquid-phase separator (7). In Figure 2, HFP is fed via line (13) and feed-pipe (1) to reactor (2). In the liquid phase separator (7), an HF-rich phase separates from the organics-rich phase. The HF-rich phase is returned via tops-line (8) to feed-pipe (1). The organics-rich phase flows via bottoms line (9) to distillation column (10). A stream comprising HFP and essentially all the hydrogen fluoride content of the stream entering distillation column (10) via line (9) is removed from the top of distillation column (10) via line (12) and the product stream HFC 227ea is removed from the bottom of column (10) via exit pipe (11).

In Figure 3, feed pipe (1) leads to a reactor (2), which optionally contains a fluorination catalyst. Line (14) from reactor (2) is provided with a feed line (13) and is in fluid-flow communication with a liquid-phase separator (7). Tops line (8) from the liquid-phase separator (7) is in fluid-flow communication with feed-pipe (1). Bottoms line (9) from the liquid-phase separator (7) is in fluid-flow communication with a distillation column (10), which is for example a packed column. Distillation column (10) is typically operated at a pressure of around 12 bars with a tops temperature of 37°C and a bottoms temperature of around 60°C. Distillation column (10) is provided with an exit pipe for product (11) and a tops pipe (12) which is in fluid flow communication with line (14) to liquid-phase separator (7).

In operation, in Figure 3, the reactor (2) is charged through feed pipe (1) with a feed stream containing fresh hydrogen fluoride and recycled hydrogen fluoride from line (8). The product from reactor (2) comprising HFC 227ea, hydrogen fluoride and

unconverted HFP, often in the form of a ternary azeotrope, travels through product pipe (14) to the liquid-phase separator (7). HFP is fed via feed line (13) and product pipe (14) to liquid-phase separator (7). The liquid-phase separator (7) is typically operated at 0-20°C to afford better separation. In the liquid-phase separator (7), an HF-rich phase separates from the organics-rich phase. The HF-rich phase is returned via tops-line (8) to feed-pipe (1). The organics-rich phase flows via bottoms line (9) to distillation column (10). A stream comprising HFP and essentially all the hydrogen fluoride content of the stream entering distillation column (10) via line (9) is removed from the top of distillation column (10) via line (12) and returned to the liquid phase separator (7) via line (14). The product stream HFC 227ea is removed from the bottom of column (10) via exit pipe (11).

In the ternary diagram in Figure 4, compositions in the area of the figure designated A phase-separate, namely compositions comprising 0.4-0.6 mole % HF, greater than 0.4 mole % HFP and less than 0.6 mole % HFC 227ea.

The present invention is further illustrated by reference to the following Examples.

#### Examples 1-4

These examples 1-4 illustrate the liquid-phase separation of HFP 227ea from HF and the enhanced separation thereof in the presence of HFP.

In the Examples, HFC 227ea and HFP, where used, were added to HF in a 500 ml whitey bomb cooled in liquid nitrogen. The whitey bomb was provided with a double-dip arrangement such that the dip-pipes would sample from the middle of each phase. The mixture was allowed to warm to room temperature, agitated, allowed to stand for 2 hours and then analysed.

The HF phase was analysed for organics by transferring a portion of the HF phase (10g) to a smaller whitey bomb containing water. It was allowed to stand for 15 minutes then the headspace was analysed by G.C.

The organics phase was analysed for HF by bubbling a portion of the organics phase through water scrubbers containing fresh de-ionised water and ice. The water was then analysed for fluoride.

The results are shown in the Table from which it can be seen that (a) a mixture of HFC 227ea and HF phase-separates such that an organic layer and an HF-rich layer are formed (Example 1) and (b) addition of HFP to the HFC 227ea/HF mixture reduces the





## Claims

1. A process for the production of HFC 227ea by the reaction of HFP with hydrogen fluoride characterised by the Steps of
  - A. charging the reaction mixture from the reaction of HFP with hydrogen fluoride to a liquid-phase separator and allowing an organic phase and a hydrogen fluoride-rich phase to separate under gravity ;
  - B. recycling the hydrogen fluoride-rich phase separated in Step A to the reactor in which the reaction is carried out;
  - C. charging the organic-rich phase separated in Step A to a distillation column;
  - D. recovering the HFC 227ea and an hydrogen fluoride-rich mixture separately from the distillation column in Step (C); and
  - E. recycling the hydrogen fluoride-rich mixture recovered from Step D to the reactor.
2. A process as claimed in Claim 1 wherein the reaction mixture charged to the liquid-phase separator in Step (A) comprises an HFC 227ea/HF azeotrope, or azeotrope-like mixture.
3. A process as claimed in Claim 1 wherein in Step A the organic phase and the hydrogen fluoride-rich phase are allowed to separate under gravity at below ambient temperature.
4. A process as claimed in Claim 1 wherein in Step A the organic phase and the hydrogen fluoride-rich phase are allowed to separate under gravity at supra-atmospheric pressure
5. A process as claimed in Claim 1 further characterised in that the HFP is charged to the liquid-phase separator.
6. A process as claimed in Claim 1 further characterised in that the HFP is charged to the reactor.
7. A process as claimed in any one of the preceding claims wherein the mixture to be separated in the liquid-phase separator in Step (A) comprises a mole ratio of HF:HFC 227ea of between 3:7 and 6:4.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

09980641.041102



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification <sup>7</sup> : C07C 17/087, 17/38, 17/383, 19/08		A1	(11) International Publication Number: WO 00/69797
			(43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/GB00/01861		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 15 May 2000 (15.05.00)			
(30) Priority Data: 9911475.3 18 May 1999 (18.05.99) GB 60/134,657 18 May 1999 (18.05.99) US			
(71) Applicant (for all designated States except US): IMPERIAL CHEMICAL INDUSTRIES PLC [GB/GB]; Imperial Chemical House, Millbank, London SW1P 3JF (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): GIBSON, Robin, Riyadh [GB/GB]; Newton Cottage, Newton Lane, Newton-by-Chester CH3 9AX (GB). SUMMERS, Greg, Lyndon [GB/GB]; 3 Roosevelt Avenue, Lancaster LA1 5BJ (GB).			
(74) Agent: DEE, Ian, M.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).			

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PRODUCTION OF 1,1,1,2,3,3,3-HEPTAFLUOROPROPANE



(57) Abstract

Preparation of HFC 227ea by reacting HFP with hydrogen fluoride comprising the steps of charging the reaction mixture therefrom to a liquid-phase separator, allowing a HFC 227ea-rich phase and a hydrogen fluoride-rich phase to separate under gravity, recycling the separated hydrogen fluoride-rich phase, charging the HFC 227ea-rich phase to a distillation column, recovering the HFC 227ea and an HF-rich mixture separately from the distillation column; and recycling the HF-rich mixture to the reactor.

Figure 1




Figure 2




Figure 3





Figure 4



NOV 2001 NOV 201

09/980641

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing

OR

☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

**Attorney Docket Number** INE 109**First Named Inventor** Robin Riyadh Gibson, et al.**COMPLETE IF KNOWN****Application Number** 09 / 980,641**Filing Date** November 15, 2001**Group Art Unit****Examiner Name****As a below named inventor, I hereby declare that:**

My residence, mailing address, and citizenship are as stated below next to my name

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PRODUCTION OF 1,1,1,2,3,3,3-HEPTAFLUOROPROPANE

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 05/15/2000

as United States Application Number or PCT International

Application Number PCT/GB00/01861

and was amended on (MM/DD/YYYY) 05/22/2001

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
9911475.3	Great Britain	05/18/1999	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	YES <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	NO <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.
60/134,657	05/18/1999	

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION — Utility or Design Patent Application**

Direct all correspondence to:

☒ Customer Number  
or Bar Code LabelOR ☐ Correspondence address below**26568**

Name

PATENT TRADEMARK OFFICE

Address

Address

City

State

ZIP

Country

Telephone

Fax

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**NAME OF SOLE OR FIRST INVENTOR:**☐ A petition has been filed for this unsigned inventor

Given Name

(first and middle (if any)) Robin Riyadh

Family Name

or Surname Gibson

Inventor's  
Signature*Robin Riyadh*

UK

Date

25-2-2002

Residence: City

Chester

State UK

Country UK

Citizenship British

Mailing Address

Newton Cottage, Newton Lane

Mailing Address

City Chester

State Cheshire

ZIP CH3 9AX

Country UK

**NAME OF SECOND INVENTOR:**☐ A petition has been filed for this unsigned inventor

Given Name

(first and middle (if any)) Greg Lyndon

Family Name

or Surname Summers

Inventor's  
Signature*Greg Lyndon*

UK

Date

03-04-02

Residence: City

Liverpool

State Merseyside

Country UK

Citizenship British

Mailing Address

50 Plattsville rd

Mailing Address

City Liverpool

State Merseyside

ZIP L18 0HZ

Country UK

☐ Additional inventors are being named on the \_\_\_\_\_ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.